Equity Overview
Price & Market Data
Price: $2.60
Daily Change: -$0.07 / 2.69%
Daily Range: $2.32 - $2.79
Market Cap: $123,566,000
Daily Volume: 611,953
Performance Metrics
1 Week: -10.62%
1 Month: -94.20%
3 Months: -94.20%
6 Months: -94.20%
1 Year: -94.20%
YTD: -92.54%
Details
Polaryx Therapeutics, Inc., clinical-stage biotechnology company, develops small molecule and gene therapy treatments for lysosomal storage disorders. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.